Neurocrine biosciences presents real-world data on therapeutic dose attainment and dosing trends of vmat2 inhibitors in patients with tardive dyskinesia

All patients treated with ingrezza® (valbenazine) capsules reached a therapeutic dose from day one, while only approximately half of patients treated with deutetrabenazine were able to reach a therapeutic dose within six months findings presented at the academy of managed care pharmacy 2025 annual meeting san diego , march 31, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the presentation of new data from a real-world study showing that all patients with tardive dyskinesia achieved a therapeutic dose with ingrezza® (valbenazine) capsules upon initiation of treatment. this retrospective cohort study will be presented at the academy of managed care pharmacy 2025 annual meeting in houston, texas.
NBIX Ratings Summary
NBIX Quant Ranking